Gathering the record
Relay is organizing the evidence and source boundaries.
Long-acting glucagon / GLP-1 dual receptor agonist
Survodutide is a once-weekly investigational peptide that activates glucagon and GLP-1 receptors. Phase 3 obesity results and Phase 2 MASH data show meaningful human signals, while approval, long-term outcomes, and complete Phase 3 replication remain pending.
60-Second Overview
Start with what it is, why it matters, what research has shown, and what remains unknown. The science follows after the orientation.
Start here. These four answers explain why the compound matters before the page introduces the deeper science.
Survodutide is an investigational medicine designed to influence two hormone signals involved in appetite, blood-sugar control, and how the liver handles energy.
Researchers are studying whether combining a gut-hormone signal called GLP-1 with the energy-regulating hormone glucagon can affect both weight and liver disease. The program includes obesity, diabetes, and biopsy-confirmed metabolic liver inflammation.
Randomized human trials have reported average weight reduction, blood-sugar improvement, and better MASH tissue findings in defined populations. A published Phase 3 obesity trial extends the weight evidence, while gastrointestinal effects and treatment discontinuation remain important to interpretation.
Survodutide is not approved. Long-term cardiovascular and kidney outcomes, rare harms, durability after treatment ends, and confirmation of liver benefits in ongoing Phase 3 trials remain unresolved.
The research depth, routes, studies, and primary sources below explain how Relay knows—and where the evidence stops.
Research context
Published research has investigated this compound using the following study designs.
These records explain what researchers did. They are not instructions, recommendations, or a transferable protocol.
A published Phase 3 trial evaluated survodutide in adults with obesity or overweight who did not have type 2 diabetes.
Reported study administration—not a recommendation.
Research at a glance
Evidence depth, confidence, and route context explain how Relay knows—not what anyone should do.
Published Phase 3 obesity and controlled Phase 2 metabolic and biopsy-based MASH evidence are available.
Research depth describes how large and mature the overall record is. It does not tell you whether the results were positive.
Findings are substantial; approval, long-term outcomes, and pivotal MASH confirmation remain pending.
Confidence describes how reliable and consistent the conclusions are. It can be high for one outcome and low for another.
The strongest evidence type shows what the best-supported conclusions are actually based on.
Human findings are more directly relevant than animal or laboratory results, but they still apply only to the populations and outcomes studied.
Route-specific record
These are exposures used in cited research for a specific route and population—not an instruction for an individual.
Half-life describes how long it takes the measured amount in the body to fall by half. It is not a dosing recommendation.
Evidence can change by administration method. Findings from one route should not automatically be applied to another.
Evidence boundary: The trial population, escalation procedures, and 76-week outcomes cannot be converted into one transferable schedule. The study does not establish approval, long-term cardiovascular outcomes, or equivalence to independently sourced material. Amounts shown describe cited research exposure—not a dosage recommendation.
Detailed evidence
Start with the strongest supported conclusion and its main uncertainty. Claim-level records below show how the evidence changes by question, population, route, formulation, and study design.
A published 725-participant Phase 3 obesity trial plus randomized Phase 2 obesity, type 2 diabetes, and biopsy-confirmed MASH studies.
This is the strongest supported conclusion in the current human evidence—not a summary of every claim made about the compound.
Long-term cardiovascular and renal outcomes, rare-event safety, durability after discontinuation, and whether ongoing Phase 3 MASH trials confirm histologic benefit.
Keeping the main uncertainty visible prevents an early or promising finding from looking more settled than it is.
Questions people bring to the evidence
Research questions—not promises of benefit.
It combines appetite and glucose-related GLP-1 signaling with glucagon-receptor activity relevant to hepatic and energy metabolism.
The treatment-regimen estimand showed about 12–13% mean reduction versus 5.4% with placebo.
This is direct human liver evidence, not merely an inference from weight loss.
The short Phase 2 study supports biological activity in diabetes but not an approved treatment claim.
Maximum weight-loss estimates should be read alongside how many participants tolerated and completed treatment.
Phase 3 publication is not the same as regulatory approval.
Mechanisms
Survodutide (BI 456906) is a long-acting glucagon/GLP-1 receptor dual agonist designed with GLP-1-biased activity. In the 725-participant SYNCHRONIZE-1 Phase 3 trial, treatment-regimen mean weight change at 76 weeks was −12.2% and −13.0% for the two studied doses versus −5.4% with placebo; efficacy-estimand values reached −15.3% and −16.6%. Earlier controlled studies demonstrated dose-dependent weight and HbA1c reductions, and a biopsy-based Phase 2 MASH trial showed significantly more MASH improvement without worsening fibrosis than placebo. Gastrointestinal adverse events and treatment discontinuation are important tolerability boundaries. Cardiovascular, renal, long-term safety, and pivotal MASH outcomes remain under study.
A plausible mechanism can explain why a study was attempted. It does not prove that the compound improves a human outcome.
Studies
Study arms are reported for transparency. They describe what researchers did in a defined record and do not transfer across identities, routes, formulations, or populations.
A later trial phase can ask a more mature question, but it does not guarantee a positive result, regulatory approval, or relevance outside the studied population.
Randomized, double-blind, placebo-controlled 76-week trial
Adults with obesity or overweight without type 2 diabetes
Treatment-regimen mean weight change was −12.2% and −13.0% versus −5.4% with placebo; efficacy-estimand reductions reached −15.3% and −16.6%.
Study administration: Once-weekly survodutide 3.6 mg, 6.0 mg, or placebo under trial protocols
Limitations: The placebo group lost substantial weight, treatment completion was incomplete, gastrointestinal events were common, and long-term outcomes were not established.
Randomized, double-blind, placebo-controlled biopsy study
Adults with biopsy-confirmed MASH and fibrosis
A significantly larger proportion of survodutide-treated participants met the primary MASH-improvement endpoint than placebo.
Study administration: Once-weekly survodutide dose groups or placebo
Limitations: The study was Phase 2, not powered to establish clinical liver outcomes, and fibrosis improvement requires confirmation in larger longer trials.
Randomized, double-blind, placebo-controlled dose-finding trial
Adults with overweight or obesity
Survodutide produced dose-dependent weight reduction versus placebo, with gastrointestinal adverse events and discontinuations affecting interpretation.
Study administration: Multiple once-weekly survodutide dose-escalation regimens or placebo
Limitations: Phase 2 duration and dose-escalation tolerability do not establish long-term benefit-risk or an approved regimen.
Randomized dose-response trial with placebo and open-label semaglutide context
Adults with type 2 diabetes
Survodutide reduced HbA1c and body weight over 16 weeks in a dose-dependent pattern.
Study administration: Multiple survodutide regimens, placebo, and open-label semaglutide
Limitations: Short duration and an open-label active comparator do not establish long-term comparative effectiveness.
Randomized clinical-outcomes development program
Adults with MASH and moderate or advanced fibrosis
LIVERAGE is evaluating whether the Phase 2 histology signal translates into a pivotal Phase 3 benefit.
Study administration: Survodutide or placebo
Limitations: No completed outcome results were available at the evidence cutoff.
Safety snapshot
Gastrointestinal adverse events and treatment discontinuation materially affect interpretation of survodutide efficacy.
Controlled human evidenceCross-trial tolerability comparisons are unreliable because escalation schedules and populations differ.
Open sourceThe current record does not support a reliable common-versus-uncommon frequency split.
Evidence boundaryUnder-detected or under-reported events must not be described as rare.
No source-qualified compound-specific warning or contraindication is encoded in the current record.
Evidence boundaryInvestigational; Phase 3 obesity and MASH development Long-term cardiovascular and renal outcomes, rare-event safety, durability after discontinuation, and whether ongoing Phase 3 MASH trials confirm histologic benefit.
Gastrointestinal adverse events and treatment discontinuation materially affect interpretation of survodutide efficacy.
Controlled human evidenceStudy discontinuation describes what happened under a study protocol; it is not an emergency-action threshold.
Open sourceNo compound-specific patient-facing urgent-action threshold is established in the current Relay record.
Evidence boundaryRelay does not infer emergency guidance from study discontinuations, mechanism, or incomplete adverse-event reporting.
Community
Built by the community
Every structured report adds useful context about research setup, outcomes, and unwanted effects as the community dataset grows.
Publicly anonymous by default. Your account keeps reports editable and helps reduce duplicate submissions.Sources
2026-06-07 · PMID 42253238 · DOI 10.1056/NEJMoa2600751
2024-10-10 · NCT06632444
2024-06-07 · PMID 38847460
2024-02-01 · PMID 38330987
2024-01-01 · PMID 38095657
2023-10-10 · NCT06066515